Orally deliverable sequence-targeted astaxanthin nanoparticles for colitis alleviation
Authors:
- 21 December 2022
- journal article
- research article
- Published by Elsevier in Biomaterials
- Vol. 293, 121976
Abstract
No abstract availableKeywords
Funding Information
- China National Funds for Distinguished Young Scientists (31925031)
- Liaoning Revitalization Talents Program (XLYC1902120)
This publication has 46 references indexed in Scilit:
- TNFα gene silencing mediated by orally targeted nanoparticles combined with interleukin-22 for synergistic combination therapy of ulcerative colitisJournal of Controlled Release, 2018
- LAG3+ Regulatory T Cells Restrain Interleukin-23-Producing CX3CR1+ Gut-Resident Macrophages during Group 3 Innate Lymphoid Cell-Driven ColitisImmunity, 2018
- Combination of NF-kB targeted siRNA and methotrexate in a hybrid nanocarrier towards the effective treatment in rheumatoid arthritisJournal of Nanobiotechnology, 2018
- Nanoparticle formation of PVP/astaxanthin inclusion complex by solution-enhanced dispersion by supercritical fluids (SEDS): Effect of PVP and astaxanthin Z-isomer contentThe Journal of Supercritical Fluids, 2018
- Sodium Butyrate Inhibits Inflammation and Maintains Epithelium Barrier Integrity in a TNBS-induced Inflammatory Bowel Disease Mice ModelEBioMedicine, 2018
- Targeted-mitochondria antioxidants therapeutic implications in inflammatory bowel diseaseJournal of Drug Targeting, 2017
- Efficient delivery of paclitaxel into ASGPR over-expressed cancer cells using reversibly stabilized multifunctional pullulan nanoparticlesCarbohydrate Polymers, 2017
- A superoxide dismutase/catalase mimetic nanomedicine for targeted therapy of inflammatory bowel diseaseBiomaterials, 2016
- Mitochondria‐Targeting Magnetic Composite Nanoparticles for Enhanced Phototherapy of CancerSmall, 2016
- Combination Therapy for Ulcerative Colitis: Orally Targeted Nanoparticles Prevent Mucosal Damage and Relieve InflammationTheranostics, 2016